Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Sonoma Pharmaceuticals Inc
Sonoma Pharmaceuticals, Inc. engages in developing and producing Stabilized Hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. The company is headquartered in Woodstock, Georgia and currently employs 13 full-time employees. The company went IPO on 2007-01-26. The firm's product offerings include Epicyn Antimicrobial Facial Cleanser, Levicyn Antimicrobial Dermal Spray, Levicyn Antipruritic Gel, Levicyn Antipruritic Spray Gel, Celacyn Scar Management Gel and Sebuderm Topical Gel. Its products are primarily targeted at the treatment of acne, the management of scars and atopic dermatitis. The company also has its office dispense products, such as Lasercyn Dermal Spray, Lasercyn Post Procedure Gel and Regenacyn Advanced Scar Management. The firm sells its products either directly or via partners in approximately 54 countries across the world. Its subsidiaries include Aquamed Technologies, Inc., Oculus Technologies of Mexico, S.A. de C.V. and Sonoma Pharmaceuticals Netherlands B.V.
Sonoma Pharmaceuticals, Inc. engages in developing and producing Stabilized Hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. The company is headquartered in Woodstock, Georgia and currently employs 13 full-time employees. The company went IPO on 2007-01-26. The firm's product offerings include Epicyn Antimicrobial Facial Cleanser, Levicyn Antimicrobial Dermal Spray, Levicyn Antipruritic Gel, Levicyn Antipruritic Spray Gel, Celacyn Scar Management Gel and Sebuderm Topical Gel. Its products are primarily targeted at the treatment of acne, the management of scars and atopic dermatitis. The company also has its office dispense products, such as Lasercyn Dermal Spray, Lasercyn Post Procedure Gel and Regenacyn Advanced Scar Management. The firm sells its products either directly or via partners in approximately 54 countries across the world. Its subsidiaries include Aquamed Technologies, Inc., Oculus Technologies of Mexico, S.A. de C.V. and Sonoma Pharmaceuticals Netherlands B.V.
Record Revenue: Sonoma reported record quarterly revenue of $4.9 million, up 14% year-over-year and 13% sequentially.
EBITDA Progress: EBITDA loss narrowed to $1.95 million, the lowest in two years, as revenue grew and expenses declined.
Channel Shift: 42% of U.S. dermatology prescriptions were filled through mail order pharmacies, helping stabilize rebates and reduce inventory risk.
Prescription Growth: Prescriptions filled hit an all-time high of 17,410 in the quarter, up 12% year-over-year and 18% sequentially.
International Launches: New acne and scar products launched in Brazil, with shipments already exceeding contractual targets and further growth expected.
Cost Controls: Operating expenses were reduced from the prior quarter, supporting the goal of ongoing EBITDA improvement.
New Products: Epicyn Antimicrobial Facial Cleanser launched in the U.S. and Gramacyn for acne launched in Brazil, expanding the hypochlorous acid product line.
